Mark Baldry - 17 May 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Commercial Officer
Issuer ticker: XFOR
Reported as of: 17 May 2024
Net transaction value: +$19,252
SEC form: 4
Accepted by SEC: 14 Feb 2025, 16:08:25 UTC
Prior SEC filing: 16 Feb 2024
Next SEC filing: 08 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Mark Baldry filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 14 Feb 2025.

Key facts

This page summarizes Mark Baldry's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Feb 2025, 16:08.

Change

Previous filing in this sequence was filed on 16 Feb 2024.
Current net transaction value: +$19,252.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Purchase

Transaction value: $14,654
Shares: +21,646
Change %: +23%
Price: $0.6770
Shares after: 115,769
Date: 17 May 2024
Ownership: Direct
Footnotes: F1

XFOR transaction

Common Stock

Purchase

Transaction value: $4,598
Shares: +13,404
Change %: +12%
Price: $0.3430
Shares after: 129,173
Date: 15 Nov 2024
Ownership: Direct
Footnotes: F1

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +600,000
Change %: +464%
Price: $0.000000
Shares after: 729,173
Date: 12 Feb 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported.

Footnote F2

Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.